Interleukin-6 Causes Myocardial Failure and Skeletal Muscle Atrophy in Rats
Background— The impact of interleukin (IL)-6 on skeletal muscle function remains the subject of controversy. Methods and Results— The effects of 7-day subcutaneous administration of recombinant human IL-6 were examined at 3 doses, 50, 100, or 250 μg · kg −1 · d −1 , in rats. Skeletal muscle mass dec...
Saved in:
Published in | Circulation (New York, N.Y.) Vol. 111; no. 8; pp. 996 - 1005 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
Hagerstown, MD
Lippincott Williams & Wilkins
01.03.2005
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Background—
The impact of interleukin (IL)-6 on skeletal muscle function remains the subject of controversy.
Methods and Results—
The effects of 7-day subcutaneous administration of recombinant human IL-6 were examined at 3 doses, 50, 100, or 250 μg · kg
−1
· d
−1
, in rats. Skeletal muscle mass decreased dose-dependently (with increasing dose: in the diaphragm, −10%,
P
=NS; −15%,
P
=0.0561; and −15%
P
<0.05; and in the gastrocnemius, −9%,
P
=NS; −9%,
P
=NS; and −18%,
P
<0.005) because of decreases in cross-sectional area of all fiber types without alterations in diaphragm contractile properties. Cardiovascular variables showed a dose-dependent heart dilatation (for end-diastolic volume: control, 78 μL; moderate dose, 123 μL; and high dose, 137 μL,
P
<0.001), reduced end-systolic pressure (control, 113 mm Hg; moderate dose, 87 mm Hg; and high dose, 90 mm Hg;
P
=0.037), and decreased myocardial contractility (for preload recruitable stroke work: control, 79 mm Hg; moderate dose, 67 mm Hg; and high dose, 48 mm Hg;
P
<0.001). Lung edema was confirmed by an increased wet-to-dry ratio (control, 4.2; moderate dose, 4.6; and high dose, 4.5;
P
<0.001) and microscopy findings. These cardiovascular alterations led to decreases in organ blood flow, particularly in the diaphragm (control, 0.56 mL · min
−1
· g
−1
; moderate dose, 0.21 mL · min
−1
· g
−1
; and high dose, 0.23 mL · min
−1
· g
−1
;
P
=0.037). In vitro recombinant human IL-6 administration did not cause any alterations in diaphragm force or endurance capacity.
Conclusions—
IL-6 clearly caused ventilatory and peripheral skeletal muscle atrophy, even after short-term administration. Blood flow redistribution, resulting from the myocardial failure induced by IL-6, was likely responsible for this muscle atrophy, because IL-6 did not exert any direct effect on the diaphragm. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 0009-7322 1524-4539 1524-4539 |
DOI: | 10.1161/01.CIR.0000156469.96135.0D |